Saudi Arabia and Indonesia call for immediate end to Gaza catastrophe Private sector companies sign pacts worth $27 billion during visit of President Prabowo    Prince Faisal and Marco Rubio discuss over phone regional situation    Saudi Arabia and Indonesia agree to bolster bilateral ties Crown Prince and President Subianto chair first meeting of Saudi-Indonesian Supreme Coordination Council    Number of Sakani platform users exceeds 4.6 million by first half of 2025    International visitors spend nearly SR50 billion in Saudi Arabia during 1Q 2025    Saudi Arabia condemns calls for imposing Israeli sovereignty over occupied West Bank    Lacazette joins NEOM SC as Saudi Pro League newcomers boost attack with French star    Al Hilal sign Abderrazak Hamdallah on loan for Club World Cup push    Trump says Israel has agreed on terms for 60-day ceasefire in Gaza    New evidence suggests Russian forces shot down Azerbaijan Airlines Flight 8243    Iran's president halts cooperation with UN nuclear watchdog, reports say    Commerce Ministry recalls over 88,000 Anker portable chargers over fire risk    Elm, One sign MoU to enhance strategic partnership and support local content in communications and marketing sector    BTS are back: K-pop band confirm new album and tour    Saudi FM receives message from Iranian counterpart    Inzaghi hails 'historic' Al Hilal win over Man City: We climbed a mountain with no oxygen    Michelin Guide launches in Saudi Arabia with phased rollout in 2025    Al Hilal stun Manchester City in seven-goal thriller to reach Club World Cup quarterfinals    'How fragile we are': Roskilde Festival tragedy remembered 25 years on    Historic Jeddah's visual identity re-imagined through global art installations at Al-Arbaeen Lagoon    Sholay: Bollywood epic roars back to big screen after 50 years with new ending    Ministry launches online booking for slaughterhouses on eve of Eid Al-Adha    Shah Rukh Khan makes Met Gala debut in Sabyasachi    Pakistani star's Bollywood return excites fans and riles far right    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Alzheimer's experts see progress on new drugs
Published in The Saudi Gazette on 02 - 08 - 2008

Despite some recent dramatic failures, Alzheimer's disease researchers say they have never been more encouraged by the wealth of promising new treatments being studied for the brain-wasting disease.
“Twenty years ago we were at zero,” said Dr. Steven DeKosky of the University of Pittsburgh, who has been studying the problem of addressing Alzheimer's for three decades.
DeKosky led one of three panels focused on new therapies featured this week at the International Conference on Alzheimer's Disease in Chicago.
There is no cure for Alzheimer's, the most common form of dementia, and current drugs merely delay symptoms a bit.
While the most advanced drugs have focused on removing clumps of beta amyloid protein that forms plaques in the brain, researchers got their first look at therapies to address the toxic tangles caused by an abnormal build-up of the protein tau.
One, a nasal spray made by Allon Therapeutics Inc, improved some measures of memory in patients with mild cognitive impairment, a precursor to Alzheimer's, researchers reported this week.
They said findings from the three-month study were strong enough for a longer, larger study.
Another, called Rember, is a refined version of an older drug used to treat urinary tract infections called methylthioninium chloride or methylene blue.
Researchers said the drug significantly improved key measures of thinking and memory in some people with moderate Alzheimer's disease for more than a year- and- a -half.
Targeting the tangle
“We now show for the first time it is possible to halt the progression of Alzheimer's disease by targeting the tangle,” Claude Wischik, of the University of Aberdeen in Scotland and chairman of TauRX Therapeutics in Singapore, told the meeting.
Wischik said he thinks the compound keeps the tau protein from forming tangles inside brain cells and eventually from bursting them open.
“I can't make any statements about safety and efficacy,” he added.
Another promising drug is Medivation Inc's Dimebon, developed in Russia as an antihistamine.
An 18-month study of 183 patients done in that country showed it was safe and produced a persistent benefit.
How Dimebon works is not clear. Researchers said it may help protect mitochondria, the energy powerhouses of cells.
“It has many effects as opposed to having one single effect,” said Dr. Scott Turner, the incoming director of the Memory Disorders Program at Georgetown University Medical Center in Washington.
Turner said more studies will be needed to show whether Dimebon offers an advance over current treatments.
New attempts at targeting beta amyloid include a drug called PBT2 from Prana Biotechnology Ltd, which aims to keep beta amyloid from interacting with copper and zinc in the brain, a process involved in plaque formation.
In another new approach, Baxter International Inc said an intravenous therapy of antibodies derived from human plasma called Gammagard helped preserve and in some cases improve cognitive function in a nine-month study.
“We're fascinated by the mechanism, but we know nothing about whether it will be useful long-term,” DeKosky said of the study.
Disappointing path
This path of attempting to alter the course of Alzheimer's by attacking beta amyloid has been littered with disappointments.
Last August, a drug by Canadian biotech Bellus Health, formerly known as Neurochem Inc, failed to show a benefit in a study of more than 1,000 patients.
Last month, Flurizan, also known as tarenflurbil, failed to help patients in a pivotal clinical test, dealing a blow to its backers Myriad Genetics and Lundbeck.
This week, shares of Elan and Wyeth plunged on news of a weaker-than-hoped-for response in a mid-stage study of its new antibody therapy bapineuzumab. Researchers are still hopeful this drug, or one like it, will work.
“There are lots of curve balls in this research and we are not having an easy time,” said Marcelle Morrison-Bogorad, director of Alzheimer's research at the National Institute on Aging.
Meanwhile, the need for effective therapies is pressing.
An estimated 5.2 million people in the United States have Alzheimer's, according to the Alzheimer's Association, and 26 million globally -- a number projected to grow to 106 million by 2050. – Reuters __


Clic here to read the story from its source.